Mathai Mammen leaves position as JnJ Executive Vice President, Pharmaceuticals, RnD
New Brunswick: Johnson & Johnson has announced that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.
Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D. Previously, he was Senior Vice President, Cardiovascular diseases, Metabolic diseases, Immunology and Oncology at Merck.
"The Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson's industry-leading portfolio," the company stated.
Read also: Johnson and Johnson cancer drug sales help weather hit from stronger dollar
Founded in 1886, Johnson and Johnson is a Pharmaceutical industry company headquartered in New Brunswick, New Jersey, United States.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.